E-Book, Englisch, 334 Seiten
Bogdan / Villiger Valuation in Life Sciences
2. Auflage 2008
ISBN: 978-3-540-78248-3
Verlag: Springer-Verlag
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
A Practical Guide
E-Book, Englisch, 334 Seiten
ISBN: 978-3-540-78248-3
Verlag: Springer-Verlag
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
This is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.
Autoren/Hrsg.
Weitere Infos & Material
1;Foreword to the First Edition;5
2;Table of Contents;9
3;Abbreviations;12
4;Introduction;13
4.1;The Life Sciences Industry;14
4.2;Valuation;17
5;Fundamentals in Life Sciences;23
5.1;Drug Development;23
5.2;Medical Device Development and Approval;36
6;Basics of Valuation;39
6.1;Introduction;39
6.2;Fundamentals;39
6.3;Valuation Methods;57
7;Valuation in Life Sciences;95
7.1;Discounting;95
7.2;Volatility;99
7.3;Peak Sales;102
7.4;Project Valuation;116
7.5;License Contract Valuation;159
7.6;Discovery and Preclinical License Deals: What’s Realistic?;183
7.7;Early-Stage Licensing with Possible Sublicensing;185
7.8;Deconstructing Early-Stage Contracts;210
7.9;Negotiating License Deals;217
7.10;Bridging Different Assumptions in Licensing;223
7.11;Valuing Projects with Multiple Indications;227
7.12;Valuing Projects with Multiple Markets;241
7.13;Technology Valuation and Feed Rate;242
7.14;IP Valuation;244
7.15;Pipeline Valuation;252
7.16;Portfolio Management;254
7.17;Company and Stock Valuation;259
8;Exercises;297
8.1;Introduction;297
8.2;Exercises;297
8.3;Solutions;303
9;Case Studies;323
9.1;Introduction;323
9.2;Case Study 1: Creating a Term-Sheet for BT-100;323
9.3;Case Study 1: Solutions;328
9.4;Case Study 2: Bio-Tec’s Lead Compound;330
9.5;Case Study 2: Solutions;335
10;References;339
11;Index;341




